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Summary A lipopolysaccharide (BP-LPS) isolated from killed Bordetella pertussis (Tohama strain) was
determined to have low toxicity based on the mortality and decrease in body weight of BP-LPS-injected mice.
BP-LPS, administered intradermally or intraperitoneally, clearly inhibited the growth of an MM46 murine
mammary carcinoma. When compared with a toxic Escherichia coli-derived LPS, BP-LPS displayed excellent
anti-tumour activity against MH134 hepatoma and Meth A fibrosarcoma. As part of a combined
chemotherapy/immunotherapy regimen, BP-LPS also seemed to prolong the lifespan of mice inoculated with
Lewis lung carcinoma. BP-LPS thus appears to have valuable characteristics as an anti-tumour agent.
Bacterial lipopolysaccharide (LPS) and its active component,
lipid A (Gmeiner et al., 1969), are known to have anti-
tumour activity against experimental tumours (Andervont,
1936). Though LPS has been demonstrated to induce tumour
regression in humans, its severe toxic effects, which include
lethality, hepatic toxicity and disseminated immune complex
disease (DIC), has prevented its developmental application as
an anti-tumour therapeutic agent. The emergence of a low-
toxicity LPS with anti-tumour activity is essential to over-
come this problem. Many trials have been carried out and
are under investigation, such as detoxification of toxic LPS
(Qureshi et al., 1982) and a survey of active non-toxic
derivatives of LPS or lipid A. Our approach to this problem
is to seek less toxic LPSs with anti-tumour activity among
the natural LPSs of several bacteria.
We previously reported that systemic administration of the
killed vaccine of a Gram-negative bacterium, Bordetella per-
tussis Tohama strain, causes significant growth inhibition of
tumours and induces no symptoms of toxicity in tumour-
bearing mice (Minagawa et al., 1988, 1990). This encouraged
us to attempt to find a less toxic LPS from this vaccine.
Here, we report that LPS isolated from Bordetella pertussis
killed vaccine (Tohama strain, BP-LPS) is less toxic than
other LPSs isolated from enterobacteria (such as Escherichia
coli), yet possesses similar anti-tumour properties. Therefore,
a tolerable dosage of BP-LPS, which could be increased
because of its low toxicity, displayed more potent anti-
tumour activity against several murine tumours than did E.
coli-derived LPS.
Materials and methods
Animals and tumours
Male C3H/HeN, Balb/c and C57BL/6 mice were used in the
experiments on anti-tumour activity at 6 weeks of age, and
4-week-old male ICR mice were used in the toxicity tests.
These animals were purchased from Shizuoka Experimental
Animal Corporation (Hamamatsu, Japan). MM46 mammary
carcinoma and MH134 hepatoma were maintained in C3H/
HeN mice, and Meth A fibrosarcoma was maintained in
Balb/c mice by weekly passage. Lewis lung carcinoma was
donated by T. Tashiro (Cancer Chemotherapy Center,
Japanese Foundation for Cancer Research, Tokyo, Japan)
and was passaged subcutaneously in the flank of C57BL/6
mice once every 2 weeks.
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Chemical reagents
Bordetella pertussis killed vaccine (BPV), which contained
approximately 2 x 10"' killed cells in 1 ml of saline, was
obtained from the Chiba Serum Institute (Chiba, Japan).
BP-LPS (Tohama strain), which was phenol-water extracted,
purified by repeated alcohol precipitation and lyophilised,
was provided by the Biotechnology Research Center, Teikyo
University (Kawasaki, Japan). E. coli LPS (0127:B8) was
purchased from Difco Lab (Detroit, MI, USA). Salmonella
typhimurium LPS (S, Ra, Rc) was purchased from Sigma (St
Louis, MO, USA). BP-LPS (165 strain) and detoxified
endotoxin (monophosphoryl-lipid A from S. typhimurium
type Re) was purchased from Ribi Immunochemical Re-
search (Hamilton, MT, USA) (Ribi, 1984). A stock solution
of 2 mg ml1' was prepared and stored at 4°C. During
preparation and before use, the solution was warmed and
sonicated to ensure solubilisation. OK432 was kindly pro-
vided by Chugai Pharmaceutical (Tokyo, Japan), lentinan by
Ajinomoto (Kawasaki, Japan) and cyclophosphamide (CY)
was purchased from Shionogi (Osaka, Japan).
Toxicity assay
The lethal toxicity of LPS was tested in normal and
galactosamine-loaded mice. Graded doses of LPS in 0.2 ml of
saline were injected intravenously (i.v.) into male 8-week-old
C3H/HeN mice. Death of the animals as a result of intoxica-
tion was observed over a 30 h period. The lethal toxicity of
LPS for galactosamine-loaded mice was measured as de-
scribed by Galanos et al. (1985). Male 6-week-old C57BL/6
mice were sensitised by intraperitoneal (i.p.) injection of 8 mg
of D-galactosamine hydrochloride in 0.2 ml of phosphate-
buffered saline (PBS), then immediately injected i.v. with
graded doses of LPS in 0.2 ml of saline. The death of mice
from intoxication was observed for 1 week. The toxicity of
LPS was assessed by decrease in body weight in LPS-injected
mice as described by Kotani et al. (1985). ICR male mice at 4
weeks of age were injected i.p. with graded doses of LPS in
0.5 ml of saline. The mice were weighed just before and 24 h
after the injection.
Anti-tumour test
For the anti-tumour test, 2 x 105 cells of MM46 mammary
carcinoma or MH134 hepatoma, suspended in 0.2 ml of
PBS(-), were inoculated subcutaneously into C3H/HeN
mice. Similarly, 2 x 105 cells of Meth A fibrosarcoma or
Lewis lung carcinoma were inoculated subcutaneously into
Balb/c or C57BL/6 mice. These tumour-bearing mice received
i.v. or intradermal (i.d.) injection of BP-LPS.
In combination therapy, OK432, cyclophosphamide, len-
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tinan and BP-LPS were administered to C57BL/6 mice inocu-
lated with Lewis lung carcinoma as described previously
(Abe et al., 1985). OK432 was injected in the tumour lesions
on days 4, 7 and 10, and CY was injected i.p. on days 12, 16
and 20. Lentinan was injected i.p. and BP-LPS was injected
i.v. on days 20, 24 and 28. The largest and smallest diameters
of each tumour were measured with a slide caliper and the
average diameter (mm) was calculated. The significance of
differences in each value was tested using Student's t-test or
log-rank test.
Results
Toxicity ofBP-LPS
Toxicity of BP-LPS (Tohama strain) was compared with
those of other Gram-negative bacteria, and its lethality in
normal mice is shown in Figure 1. The LD50 of BP-LPS
(Tohama strain) in normal C3H/HeN mice was about 0.8 mg
per mouse, which was about 10-fold higher than the LD50 of
E. coli LPS (less than 801tg per mouse). The lethal toxicity of
these LPSs in galactosamine-loaded C57BL/6 mice was also
tested. The LD50 of BP-LPS (Tohama strain) was more than
40 ng per mouse, 7-fold higher than that of E. coli LPS (6 ng
per mouse) and more than 20-fold higher than that of S.
typhimurium LPS (<2 ng per mouse) (data not shown).
As described below, the lethal toxicity of BP-LPS in
tumour-bearing mice was also observed to be less than that
of E. coli LPS. Thus, in comparison with E. coli LPS,
BP-LPS was less toxic in terms of lethality in both normal
and galactosamine-loaded mice.
LPS toxicity was also evaluated by decrease in the body
weight of mice. Each LPS was injected i.p. at a dose of 3itg
per mouse. Figure 2 shows that most LPSs, except BP-LPS
(Tohama strain) and detoxified LPSs, induced a statistically
significant decrease in body weight. The results of similar
experiments also indicated that BP-LPS, at doses up to 15 1tg
per mouse, did not significantly reduce body weight (data not
shown). These results suggest that BP-LPS (Tohama strain)
and detoxified LPS can be classified as a low-toxic LPS
distinctive from other LPSs, at least based on their ability to
decrease body weight.
Anti-tumour activity ofBP-LPS
The therapeutic effect of BP-LPS against biological response
modifier (BRM)-susceptible tumours, such as MM46 murine
mammary carcinoma, was examined. This carcinoma is
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Figure 1 Lethal toxicity of BP-LPS. Male C3H/HeN mice
(n = 5) were injected i.v. with the indicated doses of LPS in
0.2 ml of saline. The 50% lethal doses of BP-LPS (0) and E. coli
LPS (0) were calculated to be 800 jg per mouse and less than
80 jig per mouse, respectively, by the method of Behrens and
Karber (1935).
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Figure 2 Reduction in body weight caused by LPSs. The effect
of various LPSs on body weight was measured in male ICR mice
(4 weeks ofage) following i.p. injection of 3 1lg per mouse of each
LPS (in 0.2 ml of saline) (n = 6-9). The mice were weighed
before and 24 h after the injection of LPS and reduction in body
weight of those injected was calculated. *'Statistically different
from control (P<0.01).
highly antigenic (Masuko et al., 1982), and its growth has
been reported to be inhibited by BRM, including bacterial
LPS, especially when administered 1-2 weeks after tumour
inoculation (Abe et al., 1982a). Figure 3 shows that a single
i.v. injection of a relatively small dose (151lg) of BP-LPS
caused complete tumour regression in all mice injected. This
clearly shows that BP-LPS has remarkable anti-tumour
activity against MM46 mammary carcinoma in C3H/HeN
mice. This tumour system was used to determine the anti-
tumour activity of BP-LPS administered i.d., since i.d.
administration has been reported to be the best route for
LPS to elicit anti-tumour activity without severe toxicity
(Mizuno et al., 1968). Figure 4 shows that i.d. injection of I
or 3 yg of BP-LPS into tumour-inoculated sites significantly
inhibited the growth of MM46 carcinoma, so that even a
very small dose of BP-LPS displayed anti-tumour activity
without side-effects, at least when administered locally.
Next, we tested the anti.-tumour activity of BP-LPS against
Meth A fibrosarcoma, which has been reported, to be suscep-
tible to various kinds of LPS (Berendt et al., 1978). The
results of preliminary experiments indicated that i.v. admini-
stration of a tolerable dose of E. coli LPS or BP-LPS (I15 lAg
per mouse) at 9 and 16 days after tumour inoculation caused
only slight retardation of the tumour growth (data not
shown). An increased dose of LPS was then tested. As shown
in Figure 5, 75jg per mouse of BP-LPS or E. coli LPS
clearly inhibited the growth of the tumours. In this experi-
ment, some mice injected with E. coli LPS died from toxicity,
whereas all the mice treated with BP-LPS survived for 25
days after tumour inoculation, as expected from the LD50
value. This suggests that BP-LPS could expand the limit of
therap%eutic effectiveness of LPS, which is at present restricted
by the latter's toxicity.
The anti-tumour activities of BP-LPS and E. coli LPS
against MH134 hepatoma were also compared. This tumour
is known to be less antigenic (Abe et al., 1983) and unsuscep-
tible to BRMs such as LPS and readily to form metastatic
nodules in the lymph nodes (Abe et al., 1982b). In a
preliminary experiment, in which MH-134-hepatoma-bearing
mice were administered 375 1tg per mouse of BP-LPS and E.
coli LPS under the experimental conditions described in the
legend to Figure 6, the six mice injected with E. coli LPS died
within 1 week (data not shown), but the six BP-LPS-injected
mice survived. Tested doses of E. coli LPS were therefore
limited to less than 75jg per mouse. Figure 6 shows that1040 M. OHNISHI et al.
treatments with both LPSs in the dose range of 15-75 1tg per
mouse transiently inhibited the growth of tumours, but then
permitted regrowth 26 days after tumour inoculation. All five
mice given 375;Lg of BP-LPS survived the experiment, and
by the end of the experiment two of the tumours had
regressed. These mice were completely cured without the
occurrence of metastasis. These results indicate that BP-LPS
has therapeutic benefits in mice with a wide spectrum of
tumours, which has not been possible by other LPSs because
of their toxicity.
Combination therapy with BP-LPS and other BRMs
To estimate the therapeutic efficacy of BP-LPS on highly
metastatic tumours, its anti-tumour activity against Lewis
lung carcinoma (3LL) was examined. It is well known that
3LL in C57BL/6, which rapidly metastasises to the lungs,
hardly responds to treatment with BRM alone unless accom-
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panied by experimental chemotherapy or surgery. We have
reported that a combination therapy consisting of cyclophos-
phamide, OK432, lentinan and E. coli LPS is highly effective
against 3LL. The clinical value of this combination therapy
was diminished, however, by the toxicity of E. coli LPS (Abe
et al., 1985), so the possibility of replacing E. coli LPS with
low-toxicity BP-LPS in this anti-tumour therapeutic protocol
was evaluated.
Figure 7 suggests that BP-LPS in this combination therapy
could extend the lifespan of the 3LL-bearing mice tested. No
25
_20
E
E 15-
0
E 10
H3
u 14 16 17 21 25
4
Days after tumour inoculation
5 7 10 15 20 25
Days after tumour inoculation
Figure 3 Regression of MM46 mammary carcinoma by single
injection of BP-LPS. Mice (n = 6-8) were inoculated i.d. with
2 x 105 MM46 carcinoma cells on day 0. On day 7, they were
treated i.v. with (@) or without (0) 15jg of BP-LPS. "Statis-
tically different from control (P<0.01).
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Figure 5 Anti-tumour activity of BP-LPS against Meth A fibro-
sarcoma. Balb/c mice (n = 5) were inoculated i.d. with 2 x 105
Meth A fibrosarcoma cells on day 0. On days 9 and 16, they
received i.v. saline (0) or 75lag per mouse of BP-LPS (O), or E.
coli LPS (0). Two of five mice treated with E. coli LPS were
killed by LPS toxicity on day 10, and the others survived until
day 25.
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Figure 4 Anti-tumour activity of BP-LPS against MM46 mam-
mary carcinoma. Mice (n = 6-8) were inoculated i.d. with 2 x 105
MM46 carcinoma cells on day 0. On days 1, 2, 3 and 4, BP-LPS
was injected i.d. around the tumour-inoculated sites. (0) Con-
trol; (0) BP-LPS, I jg per mouse; (A) BP-LPS, 3 jug per mouse.
Statistically different from control (*P<0.05, **P<0.01).
Figure 6 Anti-tumour activity of BP-LPS or E. coli LPS against
MH134 hepatoma. Mice (n = 6) were inoculated intradermally
with 2 x 105 MH134 hepatoma cells on day 0. On days 9 and 16,
they received i.v. 0 (0), l5gLg (A, A), 75 ig (0, *) or 375 fig
(0) of E. coli LPS (open symbols) or BP-LPS (closed sym-
bols).
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Figure 7 Anti-tumour activity of BP-LPS in combination
therapy against Lewis lung carcinoma. Mice were inoculated i.d.
with 2 x 105 Lewis lung carcinoma cells on day 0. OK432 [3 KE
(Klinische Einheit) per mouse] was administered intralesionally
on days 4, 7 and 10. CY (100mg kg-') was administered i.p. on
days 12, 16 and 20. On days 20, 24 and 28, lentinan (6.25 mg kg-1)
was injected i.p. These mice were treated i.p. with (0) or without
(0) BP-LPS (2 mg kg-') on days 20, 24 and 28 of chemotherapy
(n = 6-7). The difference between the survival times of these two
groups of mice was suggested, but was not statistically significant
(P = 0.097). (0) Control without any treatment.
death due to BP-LPS toxicity was observed in this experi-
ment. We therefore anticipate that BP-LPS can display anti-
tumour activity in combination therapy with an appropriate
therapeutic regimen, even against tumours that are highly
resistant to BRM therapies.
Discussion
We have shown here that BP-LPS isolated from B. pertussis
(Tohama strain) is less toxic than the LPSs of other
enterobacteria (E. coli, S. typhimurium) and exhibits strong
anti-tumour activity against various murine tumours. BP-
LPS (Tohama strain) was effective against tumours unsuscep-
tible to BRM (MH-134 hepatoma and Lewis lung carcinoma)
and even at a very small dose, 1 fig per mouse (1/800 LD50),
it inhibited the growth of MM46 mammary carcinoma. As
far as we know, this is the first report showing that a MH134
hepatoma, established in. situ and more than 3 mm in
diameter, was clearly inhibited in growth by systemic treat-
ment with a single BRM without the need for combination
therapy (Abe et al., 1982b).
The toxicity of BP-LPS (Tohama strain), estimated by its
lethality in normal, galactosamine-loaded and tumour-
bearing mice, was less than that of E. coli LPS (or S.
typhimurium LPS). Toxic responses evaluated by body weight
loss after LPS injection suggested that BP-LPS (Tohama
strain) and detoxified LPS was less toxic.
Several non-toxic and immunostimulating derivatives of
LPS have been reported. One of these, monophosphoryl lipid
A, known as a detoxified LPS, is a typical lipid A derivative,
and its anti-tumour activity has been investigated extensively
(Amano et al., 1982). However, the anti-tumour activity of
these derivatives has been demonstrated only under certain
limited experimental conditions, such as intratumoral
administration and/or in combination with other treatments
(Rudbach et al., 1990).
Therefore, we can assume that BP-LPS (Tohama strain)
has much stronger anti-tumour activity than other non-toxic
LPS derivatives and is valuable as an anti-tumour agent.
LPS extracted from several strains of B. pertussis and the
chemical structures were partially clarified as reviewed by
Chaby and Caroff (1988). Our preliminary studies on chemi-
cal structure indicated that BP-LPS (Tohama strain) consists
mainly of rough-type LPS with a molecular weight between 5
and 10 kDa; no significant structural difference (type of
polysaccharide or molecular weight) from BP-LPS (165
strain) (Chaby & Caroff (1988) could be detected, however
the toxicity of BP-LPS (Tohama strain) seemed to be less
than that of BP-LPS (165 strain).
It might be suspected that the low toxicity of our BP-LPS
(Tohama strain) preparation resulted from the possible
degradation of LPS during the preparatory steps, but the fact
that the BP-LPS (Tohama strain) is very active not only in
BRM assay but also in the Limulus lysate assay (unpublished
data) rules this out. Further studies on the chemical structure
of BP-LPS remain to be performed.
We conducted this study with the view that investigation
of the biological properties of BP-LPS is important if its
characteristics as an anti-tumour agent are to be ascer-
tained.
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